자료실


Cost of Chronic Hepatitis B Infection in South Korea
Bong-Min Yang, PhD,* Cheol-Hwan Kim, MD, PhD,† and Ji-Yun Kim, MPH*

Goals: To estimate the direct medical costs of chronic hepatitis B
(CHB) infection and its liver disease sequelae in South Korea.

Background: Korea is a hepatitis B-endemic area with 5.79%
to 10.87% of males and 1.51% to 4.44% of females over 20 years of
age carrying the virus. It is estimated that 25% of carriers will develop
serious hepatitis B virus (HBV)-related complications. While
vaccination programs have reduced the prevalence of hepatitis B in
people younger than 20 years, significant CHB-related morbidity will
continue to occur for the next 15 to 30 years until the benefits of the
vaccination programs take effect.

Study: Direct medical costs for six CHB-related disease states, including
hepatocellular carcinoma and liver transplant, were estimated
for the year 2001.

Methods: Four data sources were used to gather information: the
National Health Insurance Corporation database, patients’ medical
charts, expert opinion, and patient survey data.

Results: In 2001, the total medical costs of six CHB-related diseases
were 250 million Korean Won (KRW) (equivalent to U.S. $208.6
million), based on an exchange rate of KRW 1200 = U.S. $1. Annual
treatment costs per patient ranged from KRW297,392 (U.S. $248) for
chronic hepatitis B to KRW 80.6 million (U.S. $67,156) for liver
transplant. The cost of treatment rose continuously with liver disease
progression. The main cost driver was inpatient hospitalizations (including
surgical costs).

Conclusion: CHB-related diseases are a significant cost burden to
the South Korean healthcare system. In addition to the obvious
clinical benefits, the prevention or delay of chronic hepatitis B liver
disease progression in South Korea could result in substantial economic
benefits to the whole society.

Key Words: hepatitis B, cost, treatment, disease state
(J Clin Gastroenterol 2004;38:S153–S157)
번호 제목 글쓴이 날짜 조회 수
54 미국간학회> AASLD 2005 Hepatitis B 전반적인 정리 [1] 양전호 2005.11.29 1065
53 가칭 학교건강검사규칙(입법예고) [1] file 윤구현 2005.11.25 841
52 임상적으로 간경변을 진단내릴때 근거 [1] 양전호 2005.11.25 2138
51 미국간학회>면역관용기떄의 치료법 [2] 양전호 2005.11.22 1466
50 직장정기검진에 대한 "건강검진실시기준,건강검진시행세칙"(2013.4.22) file 윤구현 2005.11.19 2414
49 <미국간학회>B형간염의 정의 [1] file 양전호 2005.11.15 1857
48 간질환 환자가 겪는 사회적 문제 [1] file 윤구현 2005.10.21 1594
47 산업안전보건법질의회시집 2004.11. 노동부 [1] file 윤구현 2005.10.14 1072
46 B형간염 바이러스 (HBV) DNA 단위 환산표 [3] file 윤구현 2005.09.15 6863
45 특정수혈부작용간염에대한보상지침 [1] file 윤구현 2005.05.27 1077
44 간염의 예방과 환자 가족 관리 [6] file 한상율 2005.05.19 5071
» Cost of Chronic Hepatitis B Infection in South Korea [3] file 한상율 2005.05.19 1472
42 만성 간염 진료에서 의료보험 문제 [5] 한상율 2005.05.16 3344
41 직장정기검진에 대한 "건강검진실시기준"(개정 전- 이후 개정됨) [2] file 윤구현 2005.04.26 2529
40 ’B형 간염바이러스 건강보유자 고용차별’ 해소를 위한 입법공청회 발제문 [4] file 윤구현 2005.04.15 1613
39 학교신체검사 개선을 위한 학교보건법 개정 방안 토론회 자료집 [1] file 윤구현 2005.01.31 1294
38 간질환 바로알기 2014년판 [6] file 윤구현 2004.12.03 5844
37 2004년 만성간염치료 가이드라인 [1] file 윤구현 2004.12.03 5895
36 2004년 의사협회 "B형 간염 보유자, 취업제한 옳은가?” 자료집 [1] file 한상율 2004.11.17 2374
35 만성 간염과 운동 [2] 한상율 2004.04.22 13754